Liver Cancer clinical trials in Alabama

11 actively recruiting liver cancer trials at 2 sites across Alabama.

Data from ClinicalTrials.gov · last refreshed 2026-04-20

Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group

NCT ID: NCT04851119

Sites in Alabama:

Children's Hospital of Alabama — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…

Sponsor: Tvardi Therapeutics, Incorporated

NCT ID: NCT05440708

Sites in Alabama:

The Kirklin Clinic of University of Alabama Birmingham Hospital — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Network

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…

Sponsor: Children's Oncology Group

NCT ID: NCT06620302

Sites in Alabama:

Children's Hospital of Alabama — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Industry

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

Sponsor: RayzeBio, Inc.

NCT ID: NCT06726161

Sites in Alabama:

Research Facility — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 2 Recruiting Industry

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.

Sponsor: AstraZeneca

NCT ID: NCT05775159

Sites in Alabama:

Research Site — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 2 Recruiting Academic/Other

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in …

Sponsor: Emory University

NCT ID: NCT05103904

Sites in Alabama:

University of Alabama at Birmingham — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 1, Phase 2 Recruiting Academic/Other

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

This is a phase Ib/II, dose escalation and dose expansion study of valemetostat (DS-3201) with atezolizumab and bevacizumab in patients advanced Hepatocellular carcinoma (HCC) who did not receive prior systemic therapy for advanced HCC.

Sponsor: University of Alabama at Birmingham

NCT ID: NCT06294548

Sites in Alabama:

University of Alabama at Birmingham — Birmingham, Alabama

View on ClinicalTrials.gov →

Phase 1 Recruiting Industry

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body bes…

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

NCT ID: NCT05208762

Sites in Alabama:

University of Alabama at Birmingham — Birmingham, Alabama
University of Alabama at Birmingham, IDS Pharmacy — Birmingham, Alabama
University of Alabama at Birmingham — Birmingham, Alabama
University of Alabama at Birmingham — Birmingham, Alabama

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Alabama:

Massive Bio SYNERGY-AI site — Birmingham, Alabama
Massive Bio SYNERGY-AI site — Mobile, Alabama

View on ClinicalTrials.gov →

Recruiting Industry

Observational Study Protocol: LIVER-R

Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multi…

Sponsor: AstraZeneca

NCT ID: NCT06252753

Sites in Alabama:

Research Site — Birmingham, Alabama
Research Site — Mobile, Alabama

View on ClinicalTrials.gov →

Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca

NCT ID: NCT07124000

Sites in Alabama:

Research Site — Birmingham, Alabama

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-04-20